Australia markets open in 6 hours 32 minutes

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1250-0.2450 (-7.27%)
As of 01:25PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 990.96M
Enterprise value 366.55M
Trailing P/E 19.92
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)27.35
Price/book (mrq)0.88
Enterprise value/revenue 10.24
Enterprise value/EBITDA 5.30

Trading information

Stock price history

Beta (5Y monthly) 0.39
52-week change 3-56.35%
S&P500 52-week change 323.23%
52-week high 38.0200
52-week low 32.6500
50-day moving average 33.4252
200-day moving average 34.4093

Share statistics

Avg vol (3-month) 31.7M
Avg vol (10-day) 31.79M
Shares outstanding 5294.05M
Implied shares outstanding 6294.05M
Float 8188.28M
% held by insiders 128.00%
% held by institutions 143.90%
Shares short (28 June 2024) 418.78M
Short ratio (28 June 2024) 49.56
Short % of float (28 June 2024) 48.30%
Short % of shares outstanding (28 June 2024) 46.39%
Shares short (prior month 31 May 2024) 418.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)-551.48%

Management effectiveness

Return on assets (ttm)-9.59%
Return on equity (ttm)-12.56%

Income statement

Revenue (ttm)35.79M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)-18.40%
Gross profit (ttm)N/A
EBITDA -203.5M
Net income avi to common (ttm)-146.9M
Diluted EPS (ttm)-0.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)698.02M
Total cash per share (mrq)2.37
Total debt (mrq)73.61M
Total debt/equity (mrq)6.52%
Current ratio (mrq)7.76
Book value per share (mrq)3.85

Cash flow statement

Operating cash flow (ttm)-41.52M
Levered free cash flow (ttm)-88.16M